Compare BHVN & NEO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | BHVN | NEO |
|---|---|---|
| Founded | 2013 | 2001 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Precision Instruments |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.4B | 1.2B |
| IPO Year | 2022 | 2008 |
| Metric | BHVN | NEO |
|---|---|---|
| Price | $11.39 | $9.52 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 14 | 8 |
| Target Price | ★ $29.08 | $13.38 |
| AVG Volume (30 Days) | 1.7M | ★ 1.9M |
| Earning Date | 05-11-2026 | 04-28-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 26.08 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | $10.63 |
| Revenue Next Year | N/A | $9.73 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $7.48 | $4.72 |
| 52 Week High | $18.57 | $13.74 |
| Indicator | BHVN | NEO |
|---|---|---|
| Relative Strength Index (RSI) | 68.12 | 64.91 |
| Support Level | $10.75 | $9.35 |
| Resistance Level | $11.92 | $10.82 |
| Average True Range (ATR) | 0.66 | 0.39 |
| MACD | 0.20 | 0.08 |
| Stochastic Oscillator | 99.48 | 97.19 |
Biohaven Ltd is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of life-changing treatments in key therapeutic areas, including immunology, neuroscience, and oncology. Its product pipeline includes Glutamate, Myostatin, Ion channels, Inflammation & Immunology, and Oncology. The company's products target diseases such as neuromuscular and metabolic diseases, antibody-drug conjugates for cancer, obsessive-compulsive disorder and others. Its pipeline products include: BHV-2000, BHV-7000, BHV-2100, BHV-8000, BHV-1310, BHV-1300, BHV-1400, BHV-1600, BHV-1530, and BHV-1500.
NeoGenomics Inc provides oncology diagnostic testing and consultative services which include technical laboratory services and professional interpretation of laboratory test results by licensed physicians or molecular experts in pathology and oncology. The company operates a network of cancer-focused testing laboratories in the United States and the United Kingdom. The company operates in a single segment and derives revenue from clients by providing clinical cancer testing, interpretation, and consultative services, molecular and NGS testing, comprehensive technical and professional services offerings, clinical trials and research, validation laboratory services, and oncology data solutions.